Welcome to our dedicated page for iTonic Holdings news (Ticker: ITOC), a resource for investors and traders seeking the latest updates and insights on iTonic Holdings stock.
iTonic Holdings Ltd reports developments tied to its brachytherapy healthcare-solutions business and its public-company status. Company updates identify Beijing Feitian's Treatment Planning System, related brachytherapy products and services, and the role of its operating subsidiary in cancer-treatment support.
Recurring corporate news also covers Nasdaq listing compliance matters, including minimum bid price requirements for the company's Class A ordinary shares, along with governance, capital-structure and material-event updates reported by the issuer.
iTonic Holdings (Nasdaq: ITOC) provided an update on its AI-enabled Treatment Planning System (TPS) Cloud Platform being developed via 60%-owned Mili Medical to support nuclear medicine and radiation treatment planning. The browser-based platform is intended to integrate AI-assisted planning, automated quality control, and standardized data management for multi-location hospital networks.
According to the company, current milestones include core cloud architecture, browser TPS, data-sharing framework, initial AI model training, and quality-control rules. The system is undergoing internal testing and clinical workflow validation, has not been clinically validated or approved by regulators, and is expected to be regulated as medical device software in China.
iTonic Holdings (NASDAQ: ITOC) received a 180-calendar day extension from Nasdaq to regain compliance with the minimum closing bid price requirement of Nasdaq Listing Rule 5550(a)(2). The new deadline is October 19, 2026, after the initial 180-day compliance period expired on April 20, 2026. If compliance is not achieved by October 19, Nasdaq will notify the company that its Class A ordinary shares will be delisted; the company may then request a review by a Nasdaq Hearings Panel.